Overview

Pilot Pharmacokinetic Study of New Nicotine Lozenge Formulations

Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the pharmacokinetic profile of nicotine following a single oral administration of three new nicotine lozenge formulations (V0474) in comparison with two reference products. The clinical and biological safety of V0474 and the lozenge acceptability will also be assessed.
Phase:
Phase 1
Details
Lead Sponsor:
Pierre Fabre Medicament
Treatments:
Nicotine